SCHEMBL25199116

SCHEMBL25199116

CCOC(=O)c1noc(C(C)C)c1O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
HSP90AA1 P07900 2/20 0.39
ALDH1A1 P00352 2/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39
CA14 Q9ULX7 2/20 0.39
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
HTT P42858 1/20 0.38
TDP2 O95551 2/20 0.38
MLYCD O95822 1/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
HSP90AB1 P08238 1/20 0.37
HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17603899 0.83 LMNA (0.43) LMNAALDH1A1HTTTDP2MLYCD
SCHEMBL25194063 0.79 LMNA (0.39) LMNAHSP90AA1ALDH1A1HTTTDP2
SCHEMBL17603720 0.78 LMNA (0.67) LMNAALDH1A1HTT
SCHEMBL7080536 0.75 ALDH1A1 (0.49) LMNAALDH1A1HTTNR1H2NR1H3
SCHEMBL17256524 0.75 SLC5A1 (0.38) LMNAALDH1A1HTTTDP2MLYCD
SCHEMBL16009163 0.74 ALDH1A1 (0.42) LMNAALDH1A1CA12CA1CA2
SCHEMBL18393249 0.73 TDP2 (0.40) LMNAALDH1A1HTTTDP2MLYCD
SCHEMBL22377306 0.73 TDP2 (0.40) LMNAALDH1A1HTTTDP2MLYCD
SCHEMBL19459399 0.73 ALDH1A1 (0.43) ALDH1A1CA12CA1CA2CA7
SCHEMBL22213904 0.71 HTT (0.47) ALDH1A1HTTHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA BOSTON INC. 2025-05-01 US disclosed
CN-118748992-A Novel modulators of aryl hydrocarbon receptors and methods of use thereof 元启(苏州)生物制药有限公司 2024-10-08 CN disclosed
EP-4430028-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) 2024-09-18 EP disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 WO disclosed
WO-2023086428-A2 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136556-A1 NOVEL MODULATORS OF THE ARYL HYDROCARBON RECEPTOR AND METHODS OF USE THEREOF AHR, ARNT, NR1H2 LMNA 4610/4885HSP90AA1 1138/4885ALDH1A1 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.